Lukas Kalinke, Sam M. Janes
European Respiratory Journal 2022 60: 2200569; DOI: 10.1183/13993003.00569-2022
Extract
A lung cancer patient's prognosis is defined by a combination of the cancer stage, which defines the cancer location and spread; the patient's performance status, acting as an indirect measure of their ability to tolerate treatment; and finally, more intrinsic tumour-related properties such as the local immune contexture and tumour genetic makeup. The latter two dictate whether immunotherapy and targeted agents are treatment options.
Histopathological biomarkers can predict survival in patients with resected lung adenocarcinoma https://bit.ly/3JN2HzL
Footnotes
-
Conflict of interest: L. Kalinke has nothing to disclose. S.M. Janes reports paid advisory roles for AstraZeneca, Bard1 Bioscience, Achilles Therapeutics and Jansen; received assistance for travel to meetings from AstraZeneca and Takeda; and is the investigator lead on grants from GRAIL Inc, GlaxoSmithKline plc and Owlstone.
- Received March 16, 2022.
- Accepted March 21, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org
